Hopp til hovedinnhold

Trombocytose

Publisert:
Sist revidert av:


  • Rokkam VR, Kotagiri R. Secondary thrombosis. Updated 2020 Aug 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan
  1. Rokkam VR, Kotagiri R. Secondary thrombosis. Updated 2020 Aug 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. www.ncbi.nlm.nih.gov  
  2. Bailey SE, Ukoumunne OC, et al. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. Br J Gen Pract. 2017 Jun;67(659):e405-e413. doi:10.3399/bjgp17X691109. PubMed PMID: 28533199. PubMed  
  3. Roaldsnes C, Holst R, Frederiksen H, Ghanima W. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. Eur J Haematol. 2017 Jan;98(1):85-93. Epub 2016 Sep 4. PMID: 27500783.
  4. Tefferi A. Approach to the patient with thrombocytosis. UpToDate, last updated Jan 09, 2019. Siden besøkt 04.05.21 www.uptodate.com  
  5. Mathur A, Samaranayake S, Storrar NP, Vickers MA. Investigating thrombocytosis published correction appears in BMJ. 2019 Dec 4;367:l4569. BMJ. 2019;366:l4183. PMID:31272949.
  6. Clarke C, Hamilton W, Price S, Bailey SE. Association of non-malignant diseases with thrombocytosis: a prospective cohort study in general practice. Br J Gen Pract. 2020 Nov 26;70(701):e852-e857. PMID: 33199294 PubMed  
  7. Bailey SE, Ukoumunne OC, et al. How useful is thrombocytosis in predicting an underlying cancer in primary care? a systematic review. Fam Pract. 2017 Feb;34(1):4-10. doi: 10.1093/fampra/cmw100. Epub 2016 Sep 28. Review. PubMed PMID: 27681942. PubMed  
  • Silje Folven Barlindhaug, spesialist i allmennmedisin, redaktør NEL